3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Leukemia, Lymphocytic, Chronic, B-Cell
10
Lymphoma, Mantle-Cell
8
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma, Follicular
7
Lymphoma, B-Cell, Marginal Zone
7
Lymphoma, Non-Hodgkin
6
Lymphoma, Large-Cell, Immunoblastic
6
Hodgkin Disease
6
Burkitt Lymphoma
6
Unspecified Adult Solid Tumor, Protocol Specific
5
Sezary Syndrome
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Mycosis Fungoides
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, Large-Cell, Anaplastic
5
Breast Neoplasms
5
Waldenstrom Macroglobulinemia
4
Prostatic Neoplasms
4
Multiple Myeloma
4
Melanoma
4
Lung Neoplasms
4
Leukemia
4
Immunoblastic Lymphadenopathy
4
Carcinoma, Non-Small-Cell Lung
4
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Accelerated Phase
3
Kidney Neoplasms
3
Carcinoma, Renal Cell
3
Blast Crisis
3
Interventions
Cyclophosphamide
20
Brentuximab Vedotin
20
fludarabine
16
Lenalidomide
13
Rituximab
12
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
pirtobrutinib
6
Doxorubicin
6
Bortezomib
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
venetoclax
3
nilotinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Diseases
×
tanespimycin
×
Clear all
NCT00113204
2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1
Completed
18 enrolled